Liu Long-tao, Wu Min, Wang Hong-xia
Shandong University of Traditional Chinese Medicine, Jinan 250355.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Sep;31(9):1196-200.
To observe the clinical effects of lipid-reducing red rice minute powder (LRRMP) on the levels of blood lipids, carotid artery intima-media thickness (IMT), and the plaque integral of hyperlipidemia patients complicated with carotid atherosclerosis.
This study was conducted from April 2005 to April 2006 according to inclusion criteria. Sixty hyperlipidemia patients complicated with carotid atherosclerosis were randomly assigned to the treatment group (20 cases), the Chinese medicine control group (CM control group, 20 cases), and the Western medicine control group (WM control group, 20 cases). They were recruited from the community of secondary machine tool factory of Jinan. Patients in the treatment group took LRRMP (175 mg/pill), one pill each time, twice daily. Patients in the CM control group took Xuezhikang Capsule (300 mg/pill), 2 pills each time, twice daily. Patients in the WM control group took Lovastatin Tablet (20 mg/tablet), 1 tablet each time, once daily. The course of treatment was 6 successive months for all. They avoided taking any lipid-regulating or anti-atherosclerotic drugs during the therapeutic course. The changes of Chinese medicine symptom scores, serum TC, TG, LDL-C, and HDL-C levels, IMT of the carotid artery, and the plaque integral before and after treatment were observed.
After 6 months of treatment the Chinese medicine symptom scores reduced in each group ( P<0.05 or P<0.01), and the treatment group was superior to WM control group (P<0.05). Serum TC, TG and LDL-C levels were significantly lowered (P<0.05 or P<0.01), showing no significant difference in inter-group comparison (P>0.05). There was no statistical significance of the serum HDL-C level in each group (P>0.05). The IMT and the plaque integral significantly reduced (P<0.05, P<0.01), showing no statistical difference among all groups. One patient in the WM control group dropped out because of transaminase elevation. No serious adverse reaction correlated with the drugs occurred during the therapeutic course in the rest two groups.
LRRMP showed definite effects on lipid-regulating and anti atherosclerosis. Its effects were equivalent to Xuezhikang Capsule and Lovastatin Tablet. Besides, it was safe and economic, and deserved further studies.
观察降脂红米细粉（LRRMP）对高脂血症合并颈动脉粥样硬化患者血脂水平、颈动脉内膜中层厚度（IMT）及斑块积分的临床疗效。
本研究于2005年4月至2006年4月按照纳入标准进行。60例高脂血症合并颈动脉粥样硬化患者被随机分为治疗组（20例）、中药对照组（CM对照组，20例）和西药对照组（WM对照组，20例）。他们来自济南第二机床厂社区。治疗组患者服用LRRMP（175毫克/丸），每次1丸，每日2次。CM对照组患者服用血脂康胶囊（300毫克/丸），每次2丸，每日2次。WM对照组患者服用洛伐他汀片（20毫克/片），每次1片，每日1次。所有患者的疗程均为连续6个月。治疗期间他们避免服用任何调脂或抗动脉粥样硬化药物。观察治疗前后中医症状评分、血清总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）和高密度脂蛋白胆固醇（HDL-C）水平、颈动脉IMT及斑块积分的变化。
治疗6个月后，各组中医症状评分均降低（P<0.05或P<0.01），且治疗组优于WM对照组（P<0.05）。血清TC、TG和LDL-C水平显著降低（P<0.05或P<0.01），组间比较差异无统计学意义（P>0.05）。各组血清HDL-C水平差异无统计学意义（P>0.05）。IMT及斑块积分显著降低（P<0.05，P<0.01），各组间差异无统计学意义。WM对照组有1例患者因转氨酶升高退出。其余两组在治疗期间未出现与药物相关的严重不良反应。
LRRMP在调脂及抗动脉粥样硬化方面显示出确切疗效。其疗效与血脂康胶囊和洛伐他汀片相当。此外，它安全经济，值得进一步研究。
